Use of an in-silico clinical trial intelligence solution to predict outcomes of tinengotinib, a potent multi-kinase small molecule FGFR inhibitor in patients with cholangiocarcinoma, based on the molecular matching score.
Ally Perlina, Milind M. Javle, Subha Krishnan, Katie Hennessy et autres
e15190 Background: Cancer genomic diversity, with a median of ~5 pathogenic molecular alterations per tumor, presents a challenge in predicting clinical outcomes of investigational therapies. Precision medicine implies the ability of a drug/drug combination to address the unique molecular profile of an …
us (code pays fourni par la source)
0 citations
Journal of Clinical Oncology